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Background: Dysmenorrhea is one of the most common acute pain 
disorders among women of reproductive age.
Aims: To compare the effects of IV paracetamol with dexketoprofen 
in patients presenting with primary dysmenorrhea to the emergency 
department.
Study Design: Randomized controlled trial.
Methods: Patients over 18 years old presenting with pelvic pain 
related to menstruation were eligible for the study. Study patients 
received 1 g paracetamol or 50 mg dexketoprofen in 100 mL normal 
saline with a 4-5 minute infusion via the intravenous route. Pain 
intensity was measured by a visual analog scale at 15 and 30 minutes. 
Patients were randomized and assigned to either of two study arms 
via sealed envelopes. Study drugs were identical in color, and thus 
both personnel and patients were blinded to the study drug. The 
dexketoprofen group comprised 49 patients, and the paracetamol 
group had 50 patients in the final analysis.
Results: The mean age of the study subjects was 20.9±2.5 and the 
mean duration of the pain was 1.9±1.7 (median: 1, interquartile range: 
1 to 2) hours. Both dexketoprofen (median change: 33, 95% CI: 
24 to 38) and paracetamol (median change: 21, 95% CI: 12 to 32) 
effectively reduced the pain at 15 minutes, which was repeated at 30 
minutes (median change: 63, 95% CI: 57 to 65 vs 55.5, 95% CI: 50 to 
59, respectively). Pain improvement in the dexketoprofen group was 
better than in the paracetamol group at 15 (median difference: 8, 95% 
CI: 0 to 16, p=0.048) and 30 (median difference: 6, 95% CI: 1 to 12, 
p=0.028) minutes, which was statistically significant but not clinically 
significant.
Conclusion: Dexketotoprofen has a better visual analogue scale score 
that is not clinically relevant compared to paracetamol.
Keywords: Dexketoprofen, dysmenorrhea, intravenous, paracetamol, 
treatment
Dysmenorrhea is one of the most common acute pain disorders, 
affects about 40% to 70% of women of reproductive age, and is a 
frequent cause that leads to time lost from work or school besides 
interfering with daily living (1,2). Dysmenorrhea is not uncommon 
and may be severe in up to 20% of women when it may influence 
daily activities (3).
Nonsteroidal anti-inflammatory drugs (NSAIDs) are drugs most 
commonly used in the treatment of primary dysmenorrhea. The 
NSAIDs that are approved by the US Food and Drug Administration 
for treatment of dysmenorrhea are: diclofenac, ibuprofen, 
ketoprofen, meclofenamate, mefenamic acid, and naproxen. 
NSAIDs are used related to findings that prostaglandins have a 
role in the pathogenesis of dysmenorrhea. Aspirin may not be as 
effective as these NSAIDs, and paracetamol as adjunctive therapy 
may be helpful for alleviating mild symptoms (1,4).
Randomized controlled trials showed that NSAIDs are effective 
options for relieving primary dysmenorrhea. In a systematic review 
of 73 randomized trials, NSAIDs were significantly more effective 
than placebo (OR: 4.50, 95% CI: 3.85-5.27) or paracetamol (OR: 
1.90, 95% CI: 1.05-3.44) (1). NSAIDs represent the mainstays of 
drug therapy. However, there is no randomized trial comparing 
the effectiveness of paracetamol and dexketoprofen as treatment 
options in patients presenting to the emergency department (ED) for 
pain relief because of primary dysmenorrhea.
Intravenous (IV) paracetamol has shown to be an effective treatment 
option in various painful conditions in the ED (5-7). The present 
study aimed to compare the effects of IV paracetamol with those of 
dexketoprofen in patients presenting with primary dysmenorrhea to 
the ED.
MATERIALS AND METHODS
Study setting and design
This prospective randomized, double-blind, controlled study was 
conducted in the ED of a tertiary care hospital with an annual 
census of 75.000 patients between December 15, 2014, and 
April 15, 2015. The central ethics committee approved the study 
(2014/70177). The clinicaltrial.gov ID is NCT02373514. The 
study was planned as a superiority trial with two intervention arms, 
IV dexketoprofen, and paracetamol. The funding of the study was 
provided by the authors.
Selection of participants
Patients over 18 years old presenting with pelvic pain related to 
menstruation were eligible for the study. All consecutive patients 
who presented with dysmenorrhea as their chief complaint were 
enrolled in the study. The analyses focused on the severity of 
pain, rather than on the length of time it lasted. Patients with signs 
of peritoneal irritation, allergy to the study drugs, history of renal 
and liver failure, alcohol or drug abuse and those whose received 
painkillers within the last six hours, or refused to give informed 
consent were excluded from the study.
Patients were enrolled in the study 24 hours/7 days a week. A 
senior resident determined the eligibility of patients. Diagnosis of 
dysmenorrhea was made by pelvic pain related to menstruation 
and history of painful cycles that resembled the present one. A 
normal physical examination without a remarkable pathology was 
also accepted as an eligible diagnosis.
Interventions
Study patients received 1 gr paracetamol (Perfalgan, Bristol 
Myers, Italy) or 50 mg dexketoprofen (Arveles, UFSA, Turkey) 
in 100 mL normal saline with a 4-5 minute infusion via the 
IV route. Study drugs were identical in color. Assignment 
of patients to one of the study arms was established in a 1:1 
ratio according to eight computerized randomization blocks 
performed before the study by a person blinded to the study. 
Patients eligible for the study were assigned to one of the study 
arms by designated numbers kept in an opaque envelope. A 
study nurse prepared the study drug and another nurse unaware 
of the study drug administered it to the patient. Physician, the 
nurse administered the drug, and the patients were all blinded 
to the study drug.
Methods of measurement
A 100 mm visual analog scale displaying the numbers as 10, 
20…100 (Zero; no pain and 100 mm; the worst pain) was 
used to measure the intensity of the pain. Pain measurements 
of patients were carried out at baseline, 15, and 30 minutes 
after administration of the study drug. Patients were blinded 
to previous VAS scores. The need for rescue drug and adverse 
events were also recorded on the study form. Drug-related side 
effects attributed to either of the drugs were evaluated in detail. 
Nausea was not accepted as a side effect if it existed before 
administration of the drug.
Outcome measures
The primary outcome measure was pain relief at 15 and 30 minutes 
after administration of the drug. Secondary outcome measures 
were the need for rescue drug and adverse effects secondary to 
study drugs.
Statistical analysis
Study data were analyzed with MedCalc, Statistical Package 
for Social Sciences 18.0 (SPSS Inc.; Chicago, IL, USA), and 
Confidence Interval Analysis software. Numerical data were 
presented as mean ± standard deviation and median interquartile 
range (IQR) and frequency data as rates. Study data were also 
expressed with 95% confidence interval (95% CI). Normality 
analysis was performed by the Kolmogorov Smirnov test. Two-
group comparisons for numerical data were performed by Mann-
Whitney U test and chi-square test for frequency data.
Power analysis gave the recommendation of a sample of 37 patients 
in each group, for 95% power and a standard deviation of 19 mm. 
All hypotheses were constructed as two-tailed, and an alpha-
critical value of 0.05 was accepted as significant. All analyses were 
performed according to the intention-to-treat principle.
RESULTS
A total of 133 patients were eligible for the study. Thirty-three 
patients were excluded from the study for various reasons, and 
one patient decided to withdraw from the study after 10 minutes of 
randomization and left the ED without rating the VAS scores (Figure 
1). Forty-nine patients in the dexketoprofen group and 50 patients in 
the paracetamol group were included in the final analysis.
The mean age of study subjects was 20.9±2.5 years, and the mean 
duration of pain was 1.9±1.7 (median: 1, IQR: 1 to 2) hours. There 
was no difference between study groups regarding age and duration 
of pain (Table 1).
Both dexketoprofen (median change: 33, 95% CI: 24 to 38) and 
paracetamol (median change: 21, 95% CI: 12 to 32) effectively 
reduced pain at 15 minutes (Figure 2, Table 2) and at 30 minutes 
(median change: 63, 95% CI: 57 to 65) vs 55.5, 95% CI: 50 to 
59; respectively) (Table 2, Figure 3). Pain improvement in the 
dexketoprofen group was better than that in the paracetamol group 
at 15 (median difference: 8; 95% CI: 0 to 16) and 30 (median 
difference: 6; 95% CI: 1 to 12) minutes, which was statistically 
significant but not clinically significant (Table 3).
One patient (2%) in dexketoprofen group and 4 patients (8%) 
in paracetamol group needed rescue drug (p=0.37). One patient 
in the dexketoprofen group reported dry mouth, and one patient 
had nausea, and one patient had both nausea and vomiting in the 
paracetamol group.
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TABLE 1. Comparison of demographics and rescue drug need in study groups





Age 21 (19 to 22) 21 (19 to 23) 0.34
Duration of pain 1 (1 to 2.3) 1 (1 to 2) 0.76
Rescue drug need (%) 1 (2) 4 (8) 0.37
IQR: interquartile range
DISCUSSION
The present study showed that either IV dexketoprofen or IV 
paracetamol effectively provided pain relief in patients presenting 
with primary dysmenorrhea to the ED. Despite better VAS scores 
with dexketoprofen over paracetamol at both 15 and 30 minutes, 
this difference was not clinically significant. Dexketoprofen is also 
associated with a reduced need for rescue drug but did not have 
statistical significance.
Dysmenorrhea, which reflects itself as severe colicky abdominal 
pain, is attributed primarily to high levels of prostaglandins in the 
body. NSAIDs act by decreasing the synthesis of prostaglandins by 
blocking the cyclooxygenase (COX) enzyme. Dexketoprofen is a 
non-selective NSAID of the aryl-propionic acid group containing 
the active S-enantiomer of racemic ketoprofen. Dexketoprofen is an 
NSAID with a relatively short half-life and rapid onset of action (8).
Paracetamol provides its analgesic effect through central anti-
nociceptive actions, specifically by inhibiting COX-3, which is a 
variant of COX-1. In addition, evidence suggests that paracetamol 
activates serotoninergic descending pathways that inhibit 
nociceptive signal transmission within the spinal cord. The most 
significant advantage of paracetamol is that it does not cause 
gastrointestinal bleeding or dyspepsia (9).
The current medical literature regarding dysmenorrhea consists 
mostly of studies examining oral forms of painkillers. We do not 
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TABLE 2. Change in pain intensity at 15 and 30 minutes 






   Baseline
   15 minutes







Change from baseline (VAS)
Median differences with 95% CI
   15 minutes
   30 minutes
33 (24 to 38)
63 (57 to 65)
21 (12 to 32)
55.5 (50 to 59)
CI: confidence interval; IQR: interquartile range; VAS: visual analog scale






Differences from baseline 
to 15 minutes
8 (0 to 16) 0.048
Differences from baseline
to 30 minutes
6 (1 to 12) 0.028
CI: confidence interval
FIG. 1. Patient flow chart.
have sufficient data regarding the effects of parenteral painkillers 
in the ED. A Cochrane meta-analysis reported that NSAIDs 
achieve pain relief between 17% and 95% (mean, 67%) of women 
with an NNT (number of patients needed to treat) value of 2.1 
compared with placebo for three to five days albeit gastrointestinal 
side effects (nausea, vomiting, and/or diarrhea) are still a concern 
(10). However, it is important to note that paracetamol remains the 
preferred choice for dysmenorrhea among young women around 
the world (11). For example, 57% of young women in Hong Kong 
use paracetamol for dysmenorrhea, which may be related to its safe 
side effect profile (1).
Despite its antipyretic and analgesic effects, paracetamol has 
little or no effect on inflammatory pathways. The analgesic effect 
of paracetamol partly emerges through supraspinal activation of 
descending serotonergic pathways, but its primary site of action 
may still be selective with variable inhibition of prostaglandin 
production (12). For acute pain management, IV paracetamol 
is both a safe and effective drug despite that its mechanism of 
action remains a controversial issue. Although most studies are 
interested in post-operative pain, IV paracetamol has been found 
to be as effective as opioids (5,6). IV paracetamol is thought 
to differ from both available IV opioids and NSAIDs by not 
being associated with adverse effects such as nausea, vomiting, 
and respiratory depression that are typically seen after opioid 
use, or the platelet dysfunction, gastritis, and renal toxicity 
that are related to NSAIDs. In the present study, the incidence 
of side effects was also rare, and this might be related to pain 
management.
A retrospective analysis of patients presenting with dysmenorrhea 
to the ED by Ayan et al. (13) reported that IV paracetamol had 
better pain relief than intramuscular diclofenac sodium at 30 
minutes. However, the study is a retrospective chart analysis rather 
than a randomized controlled trial.
It is unclear whether specific NSAIDs are more effective or safer 
than others are. Although some studies have not reported differences 
in effectiveness, others have stated that fenamates (mefenamic acid, 
tolfenamic acid, flufenamic acid, meclofenamate, bromfenac) may 
have slightly better efficacy than phenylproprionic acid derivatives 
(ibuprofen, naproxen). Both fenamates and phenylproprionic acid 
derivatives inhibit prostaglandin synthesis, but fenamates also 
block prostaglandin action, which may be responsible for their 
enhanced effectiveness in some studies (1,14,15). A systematic 
review by Zhang and Li Wan Po (1) reported that ibuprofen had the 
most favorable risk-benefit ratio among other NSAIDs and aspirin. 
They reported that paracetamol was less effective than NSAIDs 
but pointed out that their investigation was only one study and 
additional studies need to be conducted.
There are some limitations to this study. This study is a 
superiority trial, and we cannot conclude that the two drugs 
are equal. One patient withdrew informed consent and left the 
ED without assigning pain intensity on the visual analog scale. 
There is no follow-up data of study patients as to whether their 
pain recurred or they attended another medical facility because 
of their dysmenorrhea.
In conclusion, IV dexketoprofen has better VAS scores that are not 
clinically significant in both groups.
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